

Docket No.: 1169-038

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Martial RUAT et al.

: Confirmation No.: *Not yet assigned*

U.S. Patent Application No. *Not yet assigned*

Filed: *Herewith*

For: NOVEL USE OF MIFEPRISTONE AND DERIVATIVES THEREFOR AS HEDGEHOG PROTEIN SIGNALING PATHWAY MODULATORS AND APPLICATIONS OF SAME

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed with the application and no certification or fee is required.

Please note this is a PCT application in the entry of the National Phase in the U.S. and copies of the references cited were transmitted by WIPO and are believed to be in the file of the above-identified application and readily available to the Examiner. Therefore it is believed that Applicants have met all requirements regarding duty of disclosure under 37 CFR 1.56. A copy of the foreign search report is attached for the Examiner's information. Acknowledgement and consideration of these documents are respectfully requested.

Respectfully submitted,

LOWE HAUPTMAN & BERNER, LLP



William E. Beaumont  
Registration No. 30,996

1700 Diagonal Road, Suite 310  
Alexandria, Virginia 22314  
(703) 684-1111 WEB/sj  
Facsimile: (703) 518-5499  
Date: July 22, 2005

INFORMATION DISCLOSURE CITATION IN AN APPLICATION  (PTO-1449)		ATTY. DOCKET NO. 1169-038		U.S. PATENT APPLICATION NO. <b>10/543,004</b>			
		APPLICANT <b>Martial RUAT et al.</b>					
		FILING DATE Herewith		GROUP			
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS		
	4,386,085	5/1983	TEUTSCH et al.				
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
	98/48784	11/1998	WO			Yes	No
	00/24390 A1	5/2000	WO				
	00/24390	5/2000	WO				
	99/59596	11/1999	WO				
	98/27986	7/1998	WO				
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	"Auxiliary Therapeutic Use In Cancer And Related Disorders", Koide JRM, The Journal of Reproductive Medicine, Volume 43, No. 7, July 1998.						
	"The Progesterone Antagonist", Arch Fam Med./Vol. 2, January 1993.						
	"Successful mifepristone treatment of recurrent, inoperable meningioma", The Lancet, pg. 124-125, Vol. 336.						
	"Mifepristone (RU 486)", R. M. Bonelli, Nr. 6/7, Juli '92/XXXVIII.						
	"Hormonal Manipulation of Meningiomas <i>in vitro</i> ", Jeffrey J> Olson et al.						
	"Selective Activation of the Glucocorticoid Receptor by Steroid Antagonists in Human Breast Cancer and Osteosarcoma Cells", Christy J. Fryer et al., The Journal of Biological Chemistry, Vol. 275, No. 23, Issue of June 9, pp. 17771-17777, 2000.						
	"Protection Against Oxidative Stress-induced Neuronal Cell Death-A Novel Role for RU486", Christian Behl et al., European Journal of Neuroscience, Vol. 9, pp. 912-920, 1997.						
	"Slowing the Progression of Cognitive Decline in Alzheimer's Disease Using Mifepristone," Joseph K. Belanoff et al., Journal of Molecular Neuroscience, Vol. 19, 2002.						
	"RU-486 (Mifepristone) ameliorates diabetes but does not correct deficient $\beta$ -adrenergic signalling in adipocytes from mature C57BL/6J-ob/ob mice," T.W. Gettys et al., International Journal of Obesity (1997) 21, 865-873.						
EXAMINER	/Marcos Sznajdman/		DATE CONSIDERED		03/30/2009		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.